期刊文献+

肺癌抑制性抗体及其抗原的鉴定 被引量:6

A functional antibody targeting lung cancer and it′s antigen
下载PDF
导出
摘要 目的:鉴定抑制肺癌细胞生长的功能性单克隆抗体1E2及其抗原,为治疗肺癌提供有潜力的靶向抗体治疗剂和分子靶位。方法:采用活细胞荧光、MTT细胞增殖实验、ELISA、动物体内治疗实验等方法检测鼠单克隆抗体1E2对人肺癌细胞增殖的抑制、单抗与癌细胞的结合部位、单抗的亚类和单抗对肺癌移植瘤的抑制,以Western blotting和MALDI TOF质谱方法鉴定该功能性单抗的抗原。结果:单抗1E2能够与肺癌细胞GLC82和NCI-H520的细胞膜结合,在体外能够明显抑制肺癌细胞的增殖。动物实验表明单抗1E2能够抑制肺癌移植瘤的生长,抑制率达49%。Western blotting显示其抗原相对分子质量约110000,质谱鉴定该抗原为氨甲酰磷酸合成酶(carbamoyl-phosphate synthetase1,CPS1)。结论:单抗1E2能够在体内外抑制肺癌的生长,具有成为肺癌靶向治疗剂的潜力。该抗体识别的抗原CPS1可表达于肺癌细胞的细胞膜,可能是一个肺癌靶向治疗的新靶位。 Objective: To identify a functional monoclonal antibody 1E2 against lung cancer and its antigen, so as to provide a candidate antibody drug and molecule target for the anti-lung cancer therapy. Methods: The inhibition of the lung cancer cells, binding with tumor cells, isotypes, and inhibition of implanted tumor growth of 1 E2 monoclonal antibody were studied by immunofluorescence, ELISA, cell proliferation assay, and in vivo tumor treatment experiments. The corresponding antigen of 1 E2 was identified by Western blotting and MALDI-TOF mass spectrometry. Results: The 1 E2 antibody could recognize cell surface protein of lung cancer cell line GLC82 and HCI-H520 and obviously inhibited the lung cancer cell growth in vivo. Animal experiment revealed that 1 E2 antibody significantly inhibited lung tumor growth by 49%. Western blotting revealed that the molecular weight of the antigen of 1 E2 antibody was about 110 000. Mass fingerprint revealed this protein was carbamoyl-phosphate synthetase 1 ( CPS1 ). Conclusion: 1 E2 monoclonal antibody can suppress lung tumor growth in vitro and in vivo; it might become a candidate drug for targeted lung cancer treatment. CPS1, the antigen of 1E2, locates on the membrane of lung cancer cells and it may become a novel molecule target for lung caner therapy.
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 2007年第2期110-114,共5页 Chinese Journal of Cancer Biotherapy
基金 国家自然科学基金重点项目(No.30230150) 国家重点基础研究发展规划(973计划)项目(No.2002CB513106)
关键词 肺癌 功能性单克隆抗体 抗原 靶位 靶向治疗 lung cancer functional monoclonal antibody antigen target targeting therapy
  • 相关文献

参考文献21

  • 1Boyle P,Ferlay J.Cancer incidence and mortality in Europe 2004[J].Ann Oncol,2005,16(3):481-488.
  • 2Wingo PA,Ries LA,Giovino GA,et al.Annual report to the nation on the status of cancer,1973-1996,with a special section on lung cancer and tobacco smoking[J].J Natl Cancer Inst,1999,91(8):675-690.
  • 3Morris SR,Carey LA.Trastuzumab and beyond:New possibilities for the treatment of HER2-positive breast cancer[J].Oncology (Williston Park).2006,20(14):1763-1771.
  • 4Shih T,Lindley C.Bevacizumab:An angiogenesis inhibitor for the treatment of solid malignancies[J].Clin Ther,2006,28(11):1779-17802.
  • 5Cascone T,Gridelli C,Ciardiello F.Combined targeted therapies in non-small cell lung cancer:A winner strategy[J]? Curr Opin Oncol,2007,19(2):98-102.
  • 6Ramalingam S,Belani CP.Recent advances in targeted therapy for non-small cell lung cancer[J].Expert Opin Ther Targets,2007,11(2):245-257.
  • 7Zhang Y,Ran Y,Yu L,et al.Monoclonal antibody to human esophageal cancer endothelium inhibits angiogenesis and tumor growth[J].Anticancer Res,2006,26(4B):2963-2970.
  • 8Old LJ.Immunotherapy for cancer[J].Sci Am,1996,275(3):136-143.
  • 9Scott,AM,Cebon J.Clinical promise of tumour immunology[J].Lancet,1997,349(S2):19-22.
  • 10Baselga J,Norton L,Albanell J,et al.Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts[J].Cancer Res,1998,58(13):2825-2831.

同被引文献48

引证文献6

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部